Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene

Hepatocellular carcinoma (HCC) is an aggressive and chemoresistant cancer type. The development of novel therapeutic strategies is still urgently needed. Personalized or precision medicine is a new trend in cancer therapy, which treats cancer patients with specific genetic alterations. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jiunn-Chang, Liu, Tsang-Pai, Andriani, Vivin, Athoillah, Muhammad, Wang, Chih-Yang, Yang, Pei-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623741/
https://www.ncbi.nlm.nih.gov/pubmed/34834551
http://dx.doi.org/10.3390/jpm11111199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623741/
https://www.ncbi.nlm.nih.gov/pubmed/34834551
http://dx.doi.org/10.3390/jpm11111199

Ejemplares similares